Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by Dandy07on Nov 22, 2018 6:04pm
89 Views
Post# 29011778

You May or May Not Know

You May or May Not Know

So I did a little digging on Bellus Healths partners. There's enough generic information on the Bellus Pipeline site, but I also tried to find information at their parnters webpages. Here's what I found:

AMO Pharma announced in May 2018 the initiation of patient recruitment in an (Phase 2) study of AMO-01 for Phelan-McDermid Syndrome (PMS).  In pre-clinical studies on mice genetically modified to model PMS, AMO-01 was shown to have potential for therapeutic benefit in the treatment of multiple deficits in PMS. This study of AMO-01 at the Icahn School of Medicine at Mount Sinai in New York in PMS patients aged 12 to 45 years, who also have epilepsy, is currently underway and recruiting subjects. The study is expected to evaluate the safety and efficacy of AMO-01 in ten patients and is scheduled for completion in 2019.

Clincial Governmant Trials Website - AMO-01


Alzheon is a biopharma company working on the ALZ-801 drug for Alzheimers Disease(AD). 
on October 2017, the FDA designated ALZ-801 as a Fast Track development program for the investigation of Alzheimer’s disease and intends to commence a Phase 2b trial for patients that have been diagnosed with early to mild Alzheimer’s in the first half of 2019. Some general information about the drug, and a keynote is that it is patented and is orally administered.  Also, it was developed to improve gastrointestinal tolerability and the pharmacokinetic profile of tramiprosate by allowing ALZ-801 to be absorbed through the gut wall in a prodrug inactive form and metabolized into active tramiprosate after absorption into the bloodstream. (copied from their website - I am no scientist or doctor). 
I have also discoverd that Alzheon has Initiated an IPO. Although I haven't found out a date for it, Here is some other basic info on that:

Seeking Alpha OCT 5, 2018

As for Auven Therapeautics and the agreement with Kiacta Sacroidosis I haven't found anything on that other than Bellus Pipeline page.  I know the AA Amyloidosis was terminated 2 years ago, but I don't know if that included the Sacroidosis as well. 

If anyone has any other insight to Bellus or its parnters please share, I look forward to reading it, and remember, Keep calm and invest on!





 

Bullboard Posts